Abstract Details

Title The Use of Electrophysiology for Movement Disorders: Experience from a Single Academic Center’s Clinical Practice

Topic Movement Disorders

Presentation(s) P10 - Poster Session 10 (11:45 AM-12:45 PM)

Poster/Presentation
Number 3-014

Objective We aimed to assess the clinical utility of a standardized non-invasive electrophysiology protocol in altering the diagnosis and management of patients referred for evaluation of jerky movement disorders.

Background Movement disorders are typically diagnosed based on clinical history and observation during the physical exam. However, it can be difficult for even expert clinicians to differentiate between movement disorders based on these measures alone when findings are subtle, unusual, or there are overlapping phenotypes. Electrophysiology testing can be a helpful objective measure to aid in the diagnosis of movement disorders such as tremor and myoclonus.

Design/Methods In this prospective observational study, we recruited participants who were consecutively referred for characterization of jerky movements (clinically diagnosed tremor or myoclonus) under our research protocol (UCSD IRB # 191526). Participants underwent electrophysiological testing of upper and/or lower extremities, depending on the affected limbs, using two tri-axial accelerometers (Kistler, sensitivity 20mV/g) and 4-channel surface electromyography at rest and with action, and during tasks. Demographics, results from the electrophysiological testing, and changes in the clinical diagnosis and treatment regimen after the electrophysiology tests were analyzed.

Results We have recruited 22 participants (59.1% female, age range 13-82 years, mean age 59.8 years). Diagnoses included orthostatic tremor (n=6), enhanced physiological tremor (n=6), myoclonus (n=3), Parkinsonian tremor (n=2), task-specific tremor (n=2), posture-specific tremor (n=2), Holmes tremor (n=1), dystonic tremor (n=2), and functional tremor (n=2); some participants had more than one type of movement disorder. Electrophysiology changed the diagnosis of 12/22 patients (54.5%, data unavailable for 2 patients) and altered the clinical management of 11/22 patients (50%, data unavailable for 2 patients).

Conclusions Our findings support that electrophysiology is a useful tool in clinical practice to improve the diagnosis and guide treatment in patients with jerky movement disorders.

Authors/Disclosures
Katherine Longardner, MD (UCSD MEDICAL CENTER) PRESENTER	Dr. Longardner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boston Scientific. Dr. Longardner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. An immediate family member of Dr. Longardner has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Boston Scientific. An immediate family member of Dr. Longardner has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Trisalus. An immediate family member of Dr. Longardner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AstraZenica. An immediate family member of Dr. Longardner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sirtex. An immediate family member of Dr. Longardner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Society of Interventional Oncology. An immediate family member of Dr. Longardner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for France Foundation. An immediate family member of Dr. Longardner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Varian. Dr. Longardner has received research support from NIH.
Yasoda Satpathy	Ms. Satpathy has nothing to disclose.
Dietrich Haubenberger, MD, FAAN (Neurocrine Biosciences)	Dr. Haubenberger has received personal compensation for serving as an employee of Neurocrine Biosciences, Inc. Dr. Haubenberger has stock in Neurocrine Biosciences. Dr. Haubenberger has a non-compensated relationship as a Member of the Board with American Society for Experimental Neurotherapeutics that is relevant to AAN interests or activities.

��ɫ��

��ɫ��